Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)

Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)

SOUTH SAN FRANCISCO, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has been selected for
addition to the NASDAQ Biotechnology Index® (Nasdaq:^NBI). The semi-annual
re-ranking of the NASDAQ Biotechnology Index will become effective upon market
open on Monday, May 20, 2013.

The NASDAQ Biotechnology Index is designed to track the performance of a set
of NASDAQ listed securities that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark (ICB). The
NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. The
NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology
Index(SM) Fund (Nasdaq:IBB), which seeks investment results that correspond
generally to the price and yield performance, before fees and expenses, of the
NASDAQ Biotechnology Index. In addition, options based on the NASDAQ
Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on
various exchanges. For more information about the NASDAQ Biotechnology Index,
including eligibility criteria, visit www.nasdaq.com.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product,
Ravicti™(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013
and is currently being marketed in the United States.

For more information, please visit www.hyperiontx.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not
descriptions of historical facts regarding Hyperion, they are forward-looking
statements reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Forward-looking statements
contained in this press release include the effective date of the Hyperion's
inclusion on the NASDAQ Biotechnology Index. Hyperion undertakes no obligation
to update or revise any forward-looking statements. For a further description
of the risks and uncertainties relating to the business of the company in
general, see Hyperion's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on May 10, 2013, and any subsequent filings
with the Securities and Exchange Commission.

CONTACT: Jeffrey Farrow
         CFO
         Hyperion Therapeutics
         (650) 745-7816